Stability of an anticancer peptide isolated from Flathead by-products during in vitro gastrointestinal digestion

Authors

  • Rahmi Nurdiani Universitas Brawijaya
  • Todor Vasiljevic Victoria University
  • Tanoj K Singh CSIRO Australia
  • Osaana N Donkor Victoria University
  • Asep A Prihanto Universitas Brawijaya
  • Titis S Kusuma Universitas Brawijaya

DOI:

https://doi.org/10.31989/ffhd.v12i4.904

Abstract

Background: Several peptides from seafood have shown effective anticancer activities. Nonetheless, one of the most significant challenges in developing fish peptides as functional food ingredients is proving their efficacy as anticancer agents. This study was aimed to evaluate the anticancer capacity and stability of a purified peptide (H. Met-Gly-Pro-Pro-Gly-Leu-Ala-Gly-Ala-Pro-Gly-Glu-Ala-Gly-Arg.OH) during a simulated gastrointestinal (GI) digestion.

Methods: The anticancer activity of the peptide(s) before, during, and after GI digestion was analyzed against colon cancer cells (HT-29). Changes in cell morphology were assessed using an inverted microscope, while the degree of apoptosis was observed using a Muse Cell Analyzer.

Results: Results showed little or no hydrolysis of the bioactive peptide by pepsin was observed, indicating the peptide was resistant to digestion in gastric conditions. The growth of HT-29 cells was significantly inhibited (P < 0.05) by the un-digested peptide and peptide(s) present in the digesta that was yielded by gastric and gastrointestinal digestion up to 28.89%, 29.68%, and 38.3%, respectively. HT-29 cells treated with pepsin and pancreatin digested peptides showed the highest cell death (3.54±2.30%).

Conclusion: Overall, the findings showed that the purified peptide has the potency to be used in cancer therapy via oral administration and/or incorporation in food(s) applications for the treatment of specific cancer.

A picture containing diagram Description automatically generated

Keywords: bioactive peptide; digestion; fish by-products; hydrolysis

Author Biographies

  • Rahmi Nurdiani, Universitas Brawijaya
    Department of Fish Product Technology, Faculty of Fisheries and Marine Science, Universitas Brawijaya
  • Todor Vasiljevic, Victoria University
    Advanced Food Systems Research Unit, College of Health and Biomedicine, Victoria University
  • Tanoj K Singh, CSIRO Australia
    Commonwealth Scientific and Industrial Research Organization-Agriculture and Food, Australia
  • Osaana N Donkor, Victoria University
    Advanced Food Systems Research Unit, College of Health and Biomedicine, Victoria University
  • Asep A Prihanto, Universitas Brawijaya
    Department of Fish Product Technology, Faculty of Fisheries and Marine Science, Universitas Brawijaya
  • Titis S Kusuma, Universitas Brawijaya
    Department of Nutrition Science, Faculty of Medicine, Universitas Brawijaya

Downloads

Published

2022-04-29

Issue

Vol. 12 No. 4 (2022): April 2022

Section

Research Articles

License

Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request. 

 

Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.